NCT06419413Recruiting
A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population
A Transnational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 355 (estimated)
- First submitted
- 25 Apr 2024
- Start date
- 8 Jan 2024
- Primary completion date
- 8 Oct 2026
- Lead sponsor
- AstraZeneca
- Diseases
- Asthma
- NCT number
- NCT06419413
What you commit to
- Study type: Observational
- Planned participants: 355
- From 8 Jan 2024 to the primary completion date, 8 Oct 2026
- 21 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer
- Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.
Other illness
- history of alcohol or drug abuse within the past year
- history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments
- terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation
Other
- pregnant at time of an assessment
- has an altered mental status at the time of informed consent
Who the study is looking for
- Age 18 to 75 years of age
- acceptable FEV1 (according to ATS and ERS)
- compliance with study procedures All Asthma Cohorts
- physician diagnosed Asthma greater or equal to 3 months prior to screening visit
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (21)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.